Definitive Healthcare Corp. (NASDAQ:DH) Receives $5.72 Average PT from Analysts

Definitive Healthcare Corp. (NASDAQ:DH) has been assigned an average rating of “Hold” from the eleven brokerages that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $5.72.

Several analysts recently issued reports on the stock. Barclays reiterated an “underweight” rating and issued a $4.00 price objective on shares of Definitive Healthcare in a report on Monday, January 13th. Stephens started coverage on Definitive Healthcare in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 price target for the company. Finally, Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th.

Insider Activity

In other Definitive Healthcare news, insider William Moschella sold 45,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the sale, the insider now owns 433,830 shares of the company’s stock, valued at $2,039,001. The trade was a 9.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 14.84% of the company’s stock.

Hedge Funds Weigh In On Definitive Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DH. Nisa Investment Advisors LLC boosted its holdings in shares of Definitive Healthcare by 3,652.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company’s stock valued at $29,000 after buying an additional 6,794 shares in the last quarter. Point72 DIFC Ltd boosted its stake in Definitive Healthcare by 759.9% in the third quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock valued at $42,000 after acquiring an additional 8,215 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Definitive Healthcare during the third quarter worth about $55,000. Bleakley Financial Group LLC acquired a new stake in shares of Definitive Healthcare during the third quarter worth about $74,000. Finally, Glenmede Trust Co. NA increased its position in shares of Definitive Healthcare by 41.1% during the third quarter. Glenmede Trust Co. NA now owns 18,423 shares of the company’s stock worth $82,000 after purchasing an additional 5,362 shares in the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Stock Performance

NASDAQ DH opened at $4.62 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The stock’s 50 day simple moving average is $4.36 and its 200-day simple moving average is $4.46. The company has a market cap of $533.72 million, a PE ratio of -1.49, a price-to-earnings-growth ratio of 3.54 and a beta of 1.41. Definitive Healthcare has a 1-year low of $3.19 and a 1-year high of $10.62.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Thursday, November 7th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.03). Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The business had revenue of $62.70 million for the quarter, compared to analyst estimates of $61.66 million. During the same period last year, the firm earned $0.01 EPS. As a group, equities research analysts anticipate that Definitive Healthcare will post 0.15 EPS for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.